Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 4Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 16Lymphoma 15Burkitt Lymphoma 11Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Hodgkin Disease 6Lymphoma, Non-Hodgkin 5Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Melanoma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Skin Neoplasms 1Rasmussen subacute encephalitis 1Prostate Cancer, Hereditary, 7 1

Interventions

fludarabine 8Cyclophosphamide 7Specimen Handling 6Cytarabine 6fludarabine phosphate 5Methotrexate 5venetoclax 4merphos 4Whole-Body Irradiation 4calaspargase pegol 3Tacrolimus 3Spinal Puncture 3Mycophenolic Acid 3Melphalan 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Biopsy 3Asparaginase 3vedolizumab 2prednylidene 2pegaspargase 2deltacortene 2decitabine and cedazuridine drug combination 2blinatumomab 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Rituximab 2Prednisone 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Biphenotypic, Acute × Prednisone × Clear all
NCT04872790 2026-05-06

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT05761171 2026-04-21

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Children's Oncology Group

Phase 2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡